Integrated BioPharma, Inc. (INBP)
OTCMKTS · Delayed Price · Currency is USD
0.1890
+0.0040 (2.16%)
At close: Oct 9, 2026
Integrated BioPharma Ratios and Metrics
Market cap in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 6 | 6 | 11 | 6 | 10 | 15 | |
Market Cap Growth | -39.03% | -49.66% | 75.42% | -36.28% | -33.74% | -54.33% |
Enterprise Value | 4 | 3 | 9 | 6 | 10 | 19 |
Last Close Price | 0.19 | 0.18 | 0.36 | 0.21 | 0.33 | 0.50 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
PE Ratio | - | - | 13.72 | 56.44 | - | 3.90 |
PS Ratio | 0.13 | 0.13 | 0.20 | 0.13 | 0.20 | 0.27 |
PB Ratio | 0.33 | 0.32 | 0.55 | 0.33 | 0.53 | 0.81 |
P/TBV Ratio | 0.33 | 0.32 | 0.55 | 0.33 | 0.53 | 0.81 |
P/FCF Ratio | 6.56 | 6.24 | 5.92 | 16.21 | 8.89 | 4.15 |
P/OCF Ratio | 4.73 | 4.50 | 5.37 | 6.70 | 8.05 | 3.66 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
EV/Sales Ratio | 0.10 | 0.07 | 0.17 | 0.13 | 0.20 | 0.35 |
EV/EBITDA Ratio | - | - | 3.96 | 11.36 | 21.85 | 6.31 |
EV/EBIT Ratio | - | - | 4.59 | 25.26 | 85.75 | 7.08 |
EV/FCF Ratio | 5.00 | 3.47 | 4.94 | 16.26 | 9.22 | 5.39 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Debt / Equity Ratio | 0.17 | 0.17 | 0.05 | 0.09 | 0.14 | 0.11 |
Debt / EBITDA Ratio | - | - | 0.30 | 1.15 | 1.91 | 0.55 |
Debt / FCF Ratio | 3.44 | 3.44 | 0.54 | 4.61 | 2.39 | 0.57 |
Net Debt / Equity Ratio | -0.08 | -0.08 | -0.13 | 0.01 | 0.07 | 0.09 |
Net Debt / EBITDA Ratio | 0.58 | 0.58 | -1.11 | 0.22 | 2.88 | 0.56 |
Net Debt / FCF Ratio | -1.56 | -1.56 | -1.39 | 0.31 | 1.22 | 0.48 |
Asset Turnover | 1.75 | 1.75 | 2.13 | 1.95 | 2.00 | 2.22 |
Inventory Turnover | 4.66 | 4.66 | 4.74 | 4.32 | 4.37 | 4.37 |
Quick Ratio | 1.35 | 1.35 | 2.13 | 1.04 | 1.21 | 0.99 |
Current Ratio | 3.00 | 3.00 | 4.42 | 2.92 | 3.39 | 3.16 |
Return on Equity (ROE) | -14.96% | -14.96% | 4.08% | 0.59% | -0.18% | 23.33% |
Return on Assets (ROA) | -6.73% | -6.73% | 4.94% | 0.61% | 0.30% | 6.77% |
Return on Invested Capital (ROIC) | -16.51% | -15.92% | 4.27% | 0.53% | -0.20% | 13.61% |
Return on Capital Employed (ROCE) | -13.80% | -13.80% | 9.80% | 1.20% | 0.60% | 13.70% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 8, 2026 | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Earnings Yield | -48.41% | -50.92% | 7.29% | 1.77% | -0.34% | 25.64% |
FCF Yield | 15.25% | 16.04% | 16.90% | 6.17% | 11.25% | 24.08% |
Buyback Yield / Dilution | 0.35% | 0.35% | -0.95% | -3.08% | 7.34% | -0.65% |